%0 Journal Article
%T Evaluation of risk factor management of patients treated on an internal nephrology ward: a pilot study
%A Gunar Stemer
%A Sonja Zehetmayer
%A Rosa Lemmens-Gruber
%J BMC Pharmacology and Toxicology
%D 2009
%I BioMed Central
%R 10.1186/1472-6904-9-15
%X Medical charts of patients treated on a single internal nephrology ward were retrospectively evaluated using a predefined data collection form. Assessment of further need for therapeutic intervention was performed.For 76.5% (n = 78) of the total study population (n = 102), there was either a possibility (39.2%, n = 40) or a need (37.3%, n = 38) for further intervention based on the overall assessment. For the risk factors of hypertension, diabetes and hyperlipidemia, the proportions of patients that require further intervention were 78.8% (n = 71), 90.6% (n = 58) and 87.9% (n = 58), respectively. Patients with diabetes or hyperlipidemia were less likely to have optimal risk factor control. The number of drugs prescribed and the number of potential drug-drug interactions were significantly higher after in-hospital treatment.Risk factor treatment needs optimisation. Risk factor management, systematic medication reviews, and screening for and management of potential drug-drug interactions deserve great attention. Clinical pharmacy services could help in the achievement of treatment goals.Health-care professionals, such as physicians, nurses, and (clinical) pharmacists, in both inpatient and outpatient settings are increasingly confronted with a growing number of patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD)[1]. Medical care for CKD patients is complex due to widespread co-morbidities and major risk factors (RF) for CKD or cardiovascular disease (CVD) [2,3]. The progression of CKD and the deterioration of kidney function from stage 1 CKD [3] to more severe stages can be slowed by optimal treatment of underlying co-morbidities and RFs, which can be accomplished with lifestyle modifications and/or different pharmacological interventions that address the treatment of hypertension, diabetes mellitus and hyperlipidemia, among others. The slowing down of disease progression is pivotal for prolonging the period before stage 5 CKD or ESRD, which
%U http://www.biomedcentral.com/1472-6904/9/15